國立高雄大學圖資館 |

Language: English

Back

Cancer immunotherapiessolid tumors and hematologic malignancies /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Cancer immunotherapiesedited by Priya Hays.
Reminder of title:	solid tumors and hematologic malignancies /
other author:	Hays, Priya.
Published:	Cham :Springer International Publishing :2022.
Description:	xvi, 315 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	CancerImmunotherapy.
Online resource:	https://doi.org/10.1007/978-3-030-96376-7
ISBN:	9783030963767$q(electronic bk.)

Cancer immunotherapiessolid tumors and hematologic malignancies /
Cancer immunotherapiessolid tumors and hematologic malignancies /[electronic resource] :edited by Priya Hays. - Cham :Springer International Publishing :2022. - xvi, 315 p. :ill. (some col.), digital ;24 cm. - Cancer treatment and research,v. 1832509-8497 ;. - Cancer treatment and research ;v. 114..

Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia -- Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.

This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.

ISBN: 9783030963767$q(electronic bk.)

Standard No.: 10.1007/978-3-030-96376-7doiSubjects--Topical Terms:

201873
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45 / C35 2022

Dewey Class. No.: 616.99406

Cancer immunotherapiessolid tumors and hematologic malignancies /
LDR:03103nmm a2200337 a 4500 001 621534
003 DE-He213
005 20220512102423.0
006 m d
007 cr nn 008maaau
008 221121s2022 sz s 0 eng d
020 $a 9783030963767$q(electronic bk.)
020 $a 9783030963750$q(paper)
024 7 $a 10.1007/978-3-030-96376-7 $2 doi
035 $a 978-3-030-96376-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45 $b C35 2022
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b C215 2022
245 0 0 $a Cancer immunotherapies $h [electronic resource] : $b solid tumors and hematologic malignancies / $c edited by Priya Hays.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a xvi, 315 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Cancer treatment and research, $x 2509-8497 ; $v v. 183
505 0 $a Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia -- Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
520 $a This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.
650 0 $a Cancer $x Immunotherapy. $3 201873
650 1 4 $a Oncology. $3 195181
650 2 4 $a Hematology. $3 274899
650 2 4 $a Genetics. $3 189015
650 2 4 $a Genomics. $3 209057
700 1 $a Hays, Priya. $3 907387
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Cancer treatment and research ; $v v. 114. $3 452091
856 4 0 $u https://doi.org/10.1007/978-3-030-96376-7
950 $a Medicine (SpringerNature-11650)